APIFormDosageIndicationTherapeutic areaDossier Availability

Apixaban

FC Tablets

2.5mg, 5mg

Thromboembolic Disorders

Blood and Blood Forming Organs

Q4 2022

Apremilast

FC Tablets

10mg, 20mg, 30mg

Psoriasis and Psoriatic arthritis

Antineoplastic and Immunomodulating Agents

Q2 2023

Bosutinib

FC Tablets

100mg, 400mg, 500mg

Chronic myeloid leukemia

Antineoplastic and Immunomodulating Agents

Q4 2022

Budesonide

Capsules

3mg

Crohn´s disease

Alimentary Tract and Metabolism

Q2 2023

Eliglustat

Capsules

84mg

Gaucher disease

Alimentary Tract and Metabolism

Q4 2024

Eltrombopag

FC Tablets

25mg, 50mg, 75mg

Thrombocytopenia

Blood and Blood Forming Organs

Q2 2023

Enzalutamide

NEW

FC Tablets

40mg

Prostate cancer

Antineoplastic and Immunomodulating Agents

Q2 2025

Eslicarbazepine

FC Tablets

200mg, 800mg

Epilepsy

Nervous System

Available

Fingolimod

Capsules

0.25mg, 0.5mg

Relapsing multiple sclerosis

Antineoplastic and Immunomodulating Agents

Available

Isavuconazole

NEW

Hard Capsules

100mg

Aspergillosis

Anti-infectives for Systemic Use

Q1 2025

Ivacaftor

FC Tablets

150mg

Cystic fibrosis

Respiratory System

Q1 2025

Lisdexamfetamine

Hard Capsules

20mg, 30mg, 40mg, 50mg, 60mg, 70mg

ADHD

Nervous System

Q1 2024

Macitentan

FC Tablets

10mg

Pulmonary arterial hypertension

Cardiovascular System

Q4 2023

Obeticholic Acid

FC Tablets

5mg, 10mg

Primary biliary Cholangitis

Alimentary Tract and Metabolism

Q4 2024

Perampanel

FC Tablets

2mg, 4mg, 6mg, 8mg, 10mg, 12mg

Epilepsy

Nervous System

Q2 2024

Pomalidomide

Capsules

1mg, 2mg, 3mg, 4mg

Multiple myeloma

Antineoplastic and Immunomodulating Agents

Q2 2023

Raltegravir

FC Tablets

400mg

600mg

HIV

Anti-infectives for Systemic Use

Under development

Rifaximine

FC Tablets

200mg

550 mg

Travellers' diarrhoea Hepatic encephalopathy

Alimentary Tract and Metabolism

Q2 2023

Q2 2023

Rivaroxaban

FC Tablets

2.5mg, 10mg, 15mg, 20mg

Thromboembolic Disorders

Blood and Blood Forming Organs

Available

Ruxolitinib

Tablets

5mg, 10mg, 15mg, 20mg

Myelofibrosis

Antineoplastic and Immunomodulating Agents

Q4 2023

Sapropterin

Soluble Tablets

100mg

Hyperphenyl- alaninaemia

Alimentary Tract and Metabolism

Available

Teriflunomide

FC Tablets

7mg, 14mg

Relapsing multiple sclerosis

Antineoplastic and Immunomodulating Agents

Available

Tolvaptan

FC Tablets

7.5mg, 15mg, 30mg, 45mg, 60mg, 90mg

Polycystic kidney disease

Cardiovascular System

Q4 2022

APIFormDosageIndicationTherapeutic areaDossier Availability

Apixaban

FC Tablets

2.5mg, 5mg

Thromboembolic Disorders

Blood and Blood Forming Organs

Q4 2022

Apremilast

FC Tablets

10mg, 20mg, 30mg

Psoriasis and Psoriatic arthritis

Antineoplastic and Immunomodulating Agents

Q2 2023

Bosutinib

FC Tablets

100mg, 400mg, 500mg

Chronic myeloid leukemia

Antineoplastic and Immunomodulating Agents

Q4 2022

Budesonide

Capsules

3mg

Crohn´s disease

Alimentary Tract and Metabolism

Q2 2023

Eliglustat

Capsules

84mg

Gaucher disease

Alimentary Tract and Metabolism

Q4 2024

Eltrombopag

FC Tablets

25mg, 50mg, 75mg

Thrombocytopenia

Blood and Blood Forming Organs

Q2 2023

Enzalutamide

NEW

FC Tablets

40mg

Prostate cancer

Antineoplastic and Immunomodulating Agents

Q2 2025

Eslicarbazepine

FC Tablets

200mg, 800mg

Epilepsy

Nervous System

Available

Fingolimod

Capsules

0.25mg, 0.5mg

Relapsing multiple sclerosis

Antineoplastic and Immunomodulating Agents

Available

Isavuconazole

NEW

Hard Capsules

100mg

Aspergillosis

Anti-infectives for Systemic Use

Q1 2025

Ivacaftor

FC Tablets

150mg

Cystic fibrosis

Respiratory System

Q1 2025

Lisdexamfetamine

Hard Capsules

20mg, 30mg, 40mg, 50mg, 60mg, 70mg

ADHD

Nervous System

Q1 2024

Macitentan

FC Tablets

10mg

Pulmonary arterial hypertension

Cardiovascular System

Q4 2023

Obeticholic Acid

FC Tablets

5mg, 10mg

Primary biliary Cholangitis

Alimentary Tract and Metabolism

Q4 2024

Perampanel

FC Tablets

2mg, 4mg, 6mg, 8mg, 10mg, 12mg

Epilepsy

Nervous System

Q2 2024

Pomalidomide

Capsules

1mg, 2mg, 3mg, 4mg

Multiple myeloma

Antineoplastic and Immunomodulating Agents

Q2 2023

Raltegravir

FC Tablets

400mg

600mg

HIV

Anti-infectives for Systemic Use

Under development

Rifaximine

FC Tablets

200mg

550 mg

Travellers' diarrhoea Hepatic encephalopathy

Alimentary Tract and Metabolism

Q2 2023

Q2 2023

Rivaroxaban

FC Tablets

2.5mg, 10mg, 15mg, 20mg

Thromboembolic Disorders

Blood and Blood Forming Organs

Available

Ruxolitinib

Tablets

5mg, 10mg, 15mg, 20mg

Myelofibrosis

Antineoplastic and Immunomodulating Agents

Q4 2023

Sapropterin

Soluble Tablets

100mg

Hyperphenyl- alaninaemia

Alimentary Tract and Metabolism

Available

Teriflunomide

FC Tablets

7mg, 14mg

Relapsing multiple sclerosis

Antineoplastic and Immunomodulating Agents

Available

Tolvaptan

FC Tablets

7.5mg, 15mg, 30mg, 45mg, 60mg, 90mg

Polycystic kidney disease

Cardiovascular System

Q4 2022

Coripharma´s dossier list, available for out-licencing. This list was last updated in June 2022.